Table 2.
Clinical characteristics and unadjusted odds ratio of DPN by glycemic control group.
Met=metformin; TZD=thiazolidinediones; SU=sulphonylurea; DM=diabetes mellitus.
| Characteristics | Glycemic Control Medication | |||||
|---|---|---|---|---|---|---|
| Met/TZD1 | No DM drug | Sulfonylurea | Met/TZD + SU | Insulin2 | P value | |
| Number of patients | 366 | 199 | 388 | 716 | 645 | - |
| Mean Age (years) | 61.2 | 62.6 | 63.7 | 62.4 | 62.2 | 0.004 |
| Mean Duration of DM (years) | 5.3 | 3.7 | 8.2 | 10.9 | 16.3 | <0.00 1 |
| Mean HbA1c (%): | 7.1 | 6.7 | 7.4 | 7.7 | 8.3 | <0.00 1 |
| % having neuropathy | 41.5% | 43.2% | 51.8% | 49.9% | 58.4% | <0.00 1 |
| Unadjusted odds ratio (95% CI) | Reference Group | 1.07 (0.76, 1.52) |
1.51† (1.14, 2.02) |
1.40† (1.09, 1.81) |
1.98† (1.53, 2.57) |
- |
1
Among the 366 patients in the Metformin/TZD category at baseline, 274 (75%) took only metformin; 39 (11%) took only a TZD; and 53 (14%) took the combination of metformin and TZD.
2
Patients in the insulin category could be on insulin alone or with any other diabetes medication.
†
Significant at α level = 0.05.